BioCryst Pharmaceuticals

Interestingly, the third neuraminidase inhibitor, peramivir, saw an incarnation after the avian fiu scare. Peramivir was developed by BioCryst Pharmaceuticals and licensed to Johnson Johnson (Chand et al., 2005). However, because the bioavailability of peramivir was low and the prospective market small, Johnson Johnson pulled out of the alliance. In 2005, peramivir was regaining its life as a possible drug delivered intravenously. 

Y. Sudhakara Babu, John A. Montgomery, and Charles E. Bugg BioCryst Pharmaceuticals, Inc., Birmingham, Alabama... 

In a structure-based drug-discovery programme in the field of influenza virus neuraminidase inhibitors, researchers at BioCryst Pharmaceuticals discovered aminocarbafuranose sialyl mimetic 89 as a very potent candidate against influenza A and B viruses [17]. To arrive at this highly substituted compound in a non-racemic format, the viable route of Scheme 14 was executed. 

---